Platelet Factor 4 Activity against P. falciparum and Its Translation to Nonpeptidic Mimics as Antimalarials  by Love, Melissa S. et al.
Cell Host & Microbe
Short ArticlePlatelet Factor 4 Activity against P. falciparum
and Its Translation to Nonpeptidic
Mimics as Antimalarials
Melissa S. Love,1,8 Melanie G. Millholland,1,8 Satish Mishra,4 Swapnil Kulkarni,1 Katie B. Freeman,5 Wenxi Pan,5
Robert W. Kavash,5 Michael J. Costanzo,5 Hyunil Jo,2 Thomas M. Daly,6 Dewight R. Williams,3 M. Anna Kowalska,7
Lawrence W. Bergman,6 Mortimer Poncz,7 William F. DeGrado,2 Photini Sinnis,4 Richard W. Scott,5
and Doron C. Greenbaum1,*
1Department of Pharmacology
2Department of Biochemistry and Molecular Biophysics
3Department of Pathology and Laboratory Medicine
University of Pennsylvania, Philadelphia, PA 19104, USA
4Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
5PolyMedix, Inc., Radnor, PA 19087, USA
6Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA 19129, USA
7Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA
8These authors contributed equally to this work
*Correspondence: dorong@upenn.edu
http://dx.doi.org/10.1016/j.chom.2012.10.017SUMMARY
Plasmodium falciparum pathogenesis is affected by
various cell types in the blood, including platelets,
which can kill intraerythrocytic malaria parasites.
Platelets could mediate these antimalarial effects
through human defense peptides (HDPs), which
exert antimicrobial effects by permeabilizing mem-
branes. Therefore, we screened a panel of HDPs
and determined that human platelet factor 4 (hPF4)
kills malaria parasites inside erythrocytes by selec-
tively lysing the parasite digestive vacuole (DV).
PF4 rapidly accumulates only within infected eryth-
rocytes and is required for parasite killing in infected
erythrocyte-platelet cocultures. To exploit this anti-
malarial mechanism, we tested a library of small,
nonpeptidic mimics of HDPs (smHDPs) and identi-
fied compounds that kill P. falciparum by rapidly
lysing the parasite DV while sparing the erythrocyte
plasma membrane. Lead smHDPs also reduced
parasitemia in a murine malaria model. Thus, identi-
fying host molecules that control parasite growth
can further the development of related molecules
with therapeutic potential.
INTRODUCTION
Malaria is a devastating disease and continues to be a global
health burden, causing significant morbidity and mortality
(Gething et al., 2011). The pathogenesis of malaria is modulated
both positively and negatively by many human cell types in
blood, including monocytes, neutrophils, and platelets (Goodier
et al., 1995; Pain et al., 2001). Recently, platelets have been
shown to bind infected erythrocytes and kill intracellular malariaCell Host &parasites (McMorran et al., 2009). Previous studies have sug-
gested that thrombocytopenia is a poor prognostic marker in
malaria (Moerman et al., 2003) and is associated with cerebral
malaria (Wassmer et al., 2008). We therefore pursued the
hypothesis that host cells found in the bloodstream that are
known to secrete proteins with host defense peptide (HDP)
activity (Tang et al., 2002) could contribute to the host’s control
of malaria parasite proliferation in the blood stage.
HDPs play a central role in the innate immune system (Finlay
and Hancock, 2004; Hancock and Lehrer, 1998; Tossi et al.,
2000; Zasloff, 2002). HDPs display broad-spectrum action
against bacteria, fungi, protozoa, and viruses, which has pro-
moted their use as leads for developing antibiotics (Zasloff,
2002). A unifying characteristic of HDPs is an amphipathic
topology in which the cationic and hydrophobic side chains
segregate onto opposing faces of the overall folded molecule.
It is thought that the physicochemical properties of HDPs, rather
than any specific sequence or structure, are responsible for their
activities. HDPs are thought to bind the membrane surface in
a noncooperative fashion and then aggregate once a threshold
concentration is reached, causing membrane permeabilization
(Christensen et al., 1988; Ludtke et al., 1995). It is believed that
amphipathic topology is essential for insertion into and disrup-
tion of membranes, leading to pathogen death. From this back-
ground, we hypothesized that naturally occurring bloodstream
HDPs, especially from platelets, might have the ability to kill
P. falciparum early in erythrocytic infection.
RESULTS
Identification of hPF4 as an Antiparasitic HDP that Kills
P. falciparum via Lysis of the Parasite DV
A screen of HDPs found in the bloodstream, secreted by a variety
of cells including platelets, neutrophils, and lymphocytes, was
performed to assess their antiparasitic activity (Figure 1A). This
screen revealed that several proteins killed P. falciparumMicrobe 12, 815–823, December 13, 2012 ª2012 Elsevier Inc. 815
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Figure 1. hPF4 Acts as a HDP against P. falciparum via Lysis of the Parasite DV
(A) Screen of human HDPs found in blood for P. falciparum killing and hemolysis at 15 mM, including Regulated upon Activation, Normal T cell Expressed, and
Secreted (RANTES); hPF4; Fibrinopeptide-A (FP-A); Fibrinopeptide-B (FP-B); Human Neutrophil Peptides 1 and 2 (HNP-1; HNP-2); and Cathelicidin (LL-37).
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hPF4 showed high potency against P. falciparum with an IC50
of 4.2 mM and no significant hemolysis. Considering local
concentrations of hPF4 have been reported to reach at least
280 mM surrounding activated platelets (Kowalska et al., 2010),
the antiparasitic IC50 of hPF4 has in vivo relevance. Platelets
harvested from wild-type (WT), mouse PF4 (mPF4) knockout
(mPF4 KO), or overexpressing hPF4 (hPF4+) mice were tested
against P. falciparum in culture with recombinant mPF4 and
hPF4 as controls (Figure 1B). Because there is no evidence to
suggest that mouse platelets bind to or are activated by human
infected erythrocytes, platelets were preactivated with AYP prior
to their addition to parasite cultures. PreactivatedWT and hPF4+
mouse platelets were able to kill P. falciparum in culture, while
littermate PF4 KO platelets showed no killing capacity. Thus it
appears that PF4 is a major antimalarial component of activated
platelets.
As membrane perturbation is an established mechanism of
action for HDPs (Bechinger, 2009; Westerhoff et al., 1989), we
examined the integrity of potential target parasite membranes
upon hPF4 treatment. Since hPF4 had little hemolytic capability,
we reasoned the erythrocyte integrity was not significantly com-
promised. Parasite plasma membrane (PPM) potential assays
showed no discernible loss of potential following 4 hr of hPF4
exposure (Figure 1C). Next, the integrity of established intra-
cellular organelle targets, including the mitochondria and lyso-
some-like digestive vacuole (DV), was assessed post-hPF4
treatment. Analysis of membrane potential revealed no perturba-
tion of the mitochondria; however, a significant loss of proton
potential was observed in the DV within minutes of treatment
(Figure 1C). To further investigate this DV perturbation, trans-
genic parasites expressing green fluorescent protein (GFP)-
tagged plasmepsin-II in the DV (Klemba et al., 2004) were treated
with hPF4 and followed by fluorescence microscopy over a
10 min time course. Parasites were assayed for both hPF4
localization using immunofluorescence analysis (IFA) and direct
GFP signal (integrity of the DV; Figure 1D). Within 1 min of
hPF4 incubation, hPF4 staining could be detected in the cyto-
plasm of only infected erythrocytes. hPF4 continued to accumu-
late over the next several minutes, wherein it entered the parasite
cytoplasm and colocalized with the parasite DV. Next, severeParasite survival was normalized to an untreated control. Artesunate (500 nM) a
without and with hemolysis, respectively. Data shown are means ± SEM.
(B) Parasite-infected erythrocytes were incubated for 24 hr with 2.53 108 platelets
5 mMAYP to induce platelet activation. Parasite survival was assayed by flow cyto
an untreated control. Recombinant hPF4 and mPF4 (10 mM) were used as positi
(C) Parasite-infected erythrocytes preincubated with rhodamine 123 (1 mM for par
LysoTracker Red and then treated over a 4 hr time course with 10 mM PF4 or a 1
10 mm in each figure.
(D) hPF4 accumulates in the infected erythrocyte cytoplasm prior to lysis of the
plasmepsin-II-GFP (PM-II-GFP) were treated with 1 mM hPF4 over a 10 min time c
infected erythrocytes until entering and inducing lysis of the parasite DV, as show
GFP [DV]; red, hPF4 IFA; blue, parasite nuclei.)
(E) Western blot analysis of erythrocyte fractions or parasite lysates shows early
parasite.
(F) ImageStream flow cytometry shows a dose-dependent increase in PM-II-GFP
upon treatment with hPF4. Intact DVs have fluorescent surface areas <0.2 mm2.
(G) TEM images reveal dissolution of the DV membrane upon treatment with 10 m
(red arrowheads). Mock-treated controls showed complete integrity of the DV m
nucleus). See also Figure S1 and Movie S1.
Cell Host &perturbation of the DV allowed GFP to diffuse throughout the
parasite cytoplasm (Figure 1D, Figures S1A and S1B). Western
blot analysis of hPF4 confirmed the IFA results showing entry
into erythrocytes by 1 min followed by accumulation into the
parasite within 5 min (Figure 1E). To assess the loss of DV integ-
rity on the population level, we utilized quantitative flow cytome-
try to first capture images of individual parasite-infected cells,
then quantitatively differentiate based on DV fluorescent surface
area (SA) intact DVs (<0.2 mm2) from lysed DVs (>2 mm2; Fig-
ure 1F, Figure S1C). hPF4 treatment caused dose-dependent
DV lysis, with nearly complete DV lysis on a population level
upon exposure to 10 mM hPF4. The loss of DV integrity was
confirmed at high resolution using transmission electron micros-
copy imaging to compare untreated and hPF4-treated parasites,
revealing the complete loss of DV integrity in the hPF4-treated
parasites versus mock-treated parasites with a clearly delin-
eated DV membrane (white arrowheads; Figure 1G, also see
Movie S1). In addition to the loss of DV organellar structure,
hemozoin crystals were seen dispersed throughout the parasite
(red arrowheads). Thus, DV lysis appears to be the primary
mechanism of hPF4 action against parasites. Parasite stages
that rely heavily on DV function were especially susceptible to
hPF4 treatment (Figure S1E).
The HDP-like C Terminus of hPF4 Has Antiparasitic
Activity
hPF4 is comprised of three domains: an N-terminal chemokine
domain, a central domain responsible for homotetramerization,
and a C-terminal amphipathic helical region with HDP activity
(Yeaman et al., 2007). To test the hypothesis that the HDP-like
C terminus has activity against the malaria parasite, the
12-residue domain (C12, Figure 2A) was synthesized and tested
against P. falciparum in vitro (Figure 2B). C12 acted similarly to
the parental protein causing loss of parasite DV integrity, was
not hemolytic, and did not perturb the PPM or mitochondrial
membrane potential after a 4 hr treatment (Figure 2D). Treatment
of PM-II-GFP parasites with 100 mM C12 led to leakage of GFP
into the parasite cytoplasm following 30 min of exposure, indi-
cating loss of DV integrity (Figure 2E, Figure S2A). In order to
ascertain localization of C12 upon treatment, we synthesized
a fluorescent version of C12 (C12-TAMRA). Figure 2F showsnd the HDP melittin (15 mM) were used as positive controls for parasite death
from either littermateWT, PF4 KO, or hPF4+mice in the presence or absence of
metry using SYTOX green as ameasurement of DNA content and normalized to
ve controls. Data shown are means ± SEM.
asite plasma membrane potential; 0.2 mM for mitochondrial potential) or 10 nM
0 mM mixture of ionophores Monensin and Nigericin (Mon/Nig). Length bar is
DV by immunofluorescence. Erythrocytes infected with parasites expressing
ourse. Within 1 min of PF4 incubation, PF4 staining is seen in the cytoplasm of
n by GFP signal diffusion through the entire parasite cytoplasm. (Green, PM-II-
accumulation of hPF4 in infected erythrocytes, followed by persistence in the
parasites with a fluorescence surface area of >2 mm2, an indication of DV lysis,
Data shown are means ± SEM (*p < 0.05, **p < 0.01).
M PF4, as well as dispersal of hemozoin fragments throughout the cytoplasm
embrane (white arrowheads), encapsulating all hemozoin crystals. (N: parasite
Microbe 12, 815–823, December 13, 2012 ª2012 Elsevier Inc. 817
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Figure 2. The C-Terminal Amphipathic Helical Domain of PF4 Retains the HDP Activity against P. falciparum
(A) Projected helical wheel of C12 with each amino acid numbered.
(B) Peptide derivatives of the PF4 C-terminal domain with lysine residues mutated to alanines to determine the necessity of positive charges for C12 antimalarial
activity. Mutated residues are denoted by ‘‘A’’ followed by the residue number. IC50s are means ± SEM (n = 3).
(C) Dose-response curves for PF4, C12, and the series of C12 lysine mutants. Data shown are means ± SEM.
(D) Parasite plasma membrane, mitochondrial, and DV potential were examined upon C12 treatment (see Figure 1B for details).
(E) C12-treated PM-II-GFP parasites showed loss of DV integrity (green, PM-II-GFP [DV]; blue, parasite nuclei.)
(F) C12-TAMRA treatment of PM-II-GFP parasites shows accumulation within infected erythrocytes and parasite bodies within 15 min of exposure, followed by
DV lysis within 60 min of treatment. See also Figure S2.
Cell Host & Microbe
PF4 and Drug-like Mimics Kill Malaria Parasites
818 Cell Host & Microbe 12, 815–823, December 13, 2012 ª2012 Elsevier Inc.
Cell Host & Microbe
PF4 and Drug-like Mimics Kill Malaria Parasitesthat C12-TAMRA entered only infected erythrocytes within
15 min of treatment, with accumulation in the parasite body and
the erythrocyte cytoplasm, while the DV remained intact. Within
60 min of treatment, GFP signal permeated throughout the
parasite body, indicating lysis of theDV. As the cationic amphipa-
thicity of HDPs is thought to be key to their mechanism of action,
we reasoned that lowering the number of charges on C12 would
adversely affect its activity. Starting at theN terminus,mutation of
the first or the first two of the four lysines caused only a minor
decrease in activity (IC50 values of 84.0 mMand 92.1 mM, respec-
tively), whilemutation of the first three lysines ablated the antipar-
asitic activity of C12 (IC50 of > 200 mM; Figures 2B and 2C). The
quadruple mutant was not tested due to its insolubility. These
data suggest that, like most HDPs, activity of the amphipathic
C12 peptide is dependent on a minimal cationic charge density.
Synthetic Small Molecule HDP Mimics Are Potent
against P. falciparum and Have a Mechanism Similar
to hPF4
Given their broad activity, HDPs appear to be ideal therapeutic
agents, though significant pharmaceutical issues have severely
hampered clinical progress, including poor tissue distribution,
systemic toxicity, and difficulty and expense of manufacturing
(Eastonet al., 2009). In addition, PF4hasbeen reported toworsen
experimental cerebral pathology in mice, presumably mediated
through the chemokine domain (Srivastava et al., 2008). Thus,
we reasoned that synthetic small molecules capable of adopting
amphipathic secondary structures analogous to a HDP could
potentially reproduce the potent, selective antiparasitic activity
of PF4while improving tissuedistribution anddecreasing compli-
cations arising fromchemokine signaling. In addition, these small
molecule HDPmimics (smHDPs) are significantly less expensive
toproduce (anexample scaffold is shown in Figure 3A). In order to
exploit the DV lysis mechanism of PF4 in a drug discovery effort,
a library of 1,000 nonpeptidic smHDPs (Scott et al., 2008) was
tested against P. falciparum. A total of 132 compounds were
determined to be initial ‘‘hits’’ (14.3% hit rate), using a cutoff of
80% parasite death at 1 mM (Z0 = 0.720; Figure 3B). Seventy-
four compounds were selected for follow-up IC50 determination
(PMX004-1120, Table S1). Based on these hits, additional
compounds were synthesized (PMX1154-1422, Table S1), and
seven structurally diverse compounds were chosen as ‘‘leads’’
based on high potency against P. falciparum, low hemolytic
potential (Figure S3A), and low mammalian cell cytotoxicity.
These lead compounds also showed similar potency across
a panel of chloroquine-sensitive (3D7, HB3) and chloroquine-
resistant (Dd2, 7G8, K1) parasite lines (Figure 3C). Several of
the lead compounds displayed little activity against Gram-posi-
tive andGram-negative bacteria andmammalian cells, indicating
that a high level of specificity can be built into these nonpeptidic
scaffolds. Secondarily, specificity can also be found between
simple single-cell eukaryotic pathogens and mammalian cells
(Figure3D).Althoughall leadcompounds showedasimilarmech-
anism of action as PF4, based on acute animal tolerability
studies, PMX1207 and PMX207 were selected for more rigorous
mechanistic analysis (structures shown in Figure 3E).
Treatment of P. falciparum parasites with either PMX1207 or
PMX207 disrupted DV membrane potential within 15 min of
treatment but did not disturb the PPM or mitochondrial potential,Cell Host &even after 4 hr treatment (Figure 4A). In addition, treatment of the
transgenic PM-II-GFP parasites with PMX1207 and PMX207 re-
sulted in rapid diffusion of GFP through the parasite cytoplasm,
indicating a catastrophic loss of DV membrane integrity in
a manner similar to that observed for hPF4 (Figure 4B; other
five leads shown in Figure S4A). Quantitative flow cytometry
analysis indicated a dose-dependent effect on DV lysis, with
nearly complete DV lysis within the treated population upon
treatment with 1 mM of PMX207 or PMX1207 (Figure 4C). We
further investigated the intracellular localization and distribution
of the smHDPs using PMX496, a potent smHDP with intrinsic
fluorescence. PMX496 appeared to accumulate in the parasite
body within 30 s, then concentrated in the DV at 1 min, prior to
dissipation throughout the parasite body, indicating a loss of
DV membrane integrity (Figure S4B). Since cationic amphipa-
thicity is predicted to be necessary for smHDP antiparasitic
action, an uncharged isosteric analog of PMX496 was synthe-
sized (PMX1269, IC50 > 2.5 mM; structures in Figure S4C). As ex-
pected, treatment with the uncharged analog did not result in DV
lysis, aswith the triple alanine C12mutant. High-resolution trans-
mission electron microscopy and 3D tomograms revealed
a complete loss of integrity of the DV after treatment with either
PMX1207 or PMX207 (Figure 4D, Movie S2). In addition to free
hemozoin crystals (red arrowheads), images showed an accu-
mulation of undigested hemoglobin-containing vesicles (yellow
arrowheads; Figure 4D, Figure S4F). Mock-treated parasites
showed clear delineating DV membranes (white arrowheads).
DV lysis and killing was also evident in Texas Red Dextran-
loaded erythrocytes infected with either trophozoite-stage
parasites (Figure S4D) or gametocytes (Figure S4E). Loss of
gametocyte DV integrity would likely result in parasite death
and indicates that smHDPs may have transmission-blocking
potential. To further assess the antimalarial capacity of
PMX207 and PMX1207, they were screened against an addi-
tional five P. falciparum isolates encompassing a diverse set of
malaria-endemic regions and antimalarial drug resistance char-
acteristics (Figure S3B). All lines were comparably susceptible
to these smHDPs, reiterating their potential as antimalarials.
HDP and smHDP Activity Reduce Parasitemia
in a Murine Malaria Model
We next tested PF4 and its HDP domain C12 in a non-experi-
mental cerebral malaria (non-ECM) murine malaria model using
the 4 day Peters’ suppression test (Knight and Peters, 1980).
mPF4 treatment significantly reduced parasitemia by 4-fold,
while the HDP domain C12 reduced parasitemia by 3-fold
(Figures S1F and S2B), indicating that the HDP domain retained
antimalarial activity during disease stages in vivo, aside from
cerebral malaria. In an ECM model (P. berghei ANKA), C12
reduced parasitemia compared to controls on day 5; however,
by day 7 (3 days after cease of treatment), parasitemia in the
C12-treated mice were significantly higher than controls (Fig-
ure S2C). These data suggest that even the C12 domain of
PF4 has some immunomodulatory activity that has a negative
impact on survival in the P. berghei ANKA model of cerebral
malaria; therefore, we felt that that the smHDPs have the best
potential as antimalarials.
In order to further explore the antimalarial properties of lead
smHDPs, PMX207 and PMX1207 were assessed for their abilityMicrobe 12, 815–823, December 13, 2012 ª2012 Elsevier Inc. 819
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Figure 3. Screen of smHDPs Reveals Potent Inhibitors of P. falciparum Growth
(A) Conceptual design of smHDPs from HDPs. Top: Amphipathic structure of magainin 2; cationic groups in blue, nonpolar groups in green, peptide backbone in
yellow. Bottom: de novo designed smHDPs capture the facially amphipathic architecture and critical physicochemical properties needed to establish robust
antimicrobial activity.
(B) Screen of 920 smHDPs at 500 nM against P. falciparum. Parasite death was normalized to a chloroquine control (14.3% hit rate, Z0 = 0.720).
(C) Lead smHDPs were screened against a panel of chloroquine-sensitive and chloroquine-resistant P. falciparum lines. Chloroquine was used as a positive
control for parasite death. IC50s are as mean ± SEM, n > 3 for each compound. Cytotoxicity (EC50) determined against mouse 3T3 fibroblasts and human
transformed liver HepG2 cells using an MTS viability assay.
(D) Comparison of anti-P. falciparum (Pf; 3D7 strain) and antibacterial activities. Bacteria strains: E. coli 25922 (EC), S. aureus 27660 (SA), E. faecalis 29212 (EF),
P. aeruginosa 10145 (PA), K. pneumoniae 13883 (KP).
(E) Chemical structures of PMX1207 and PMX207. See also Figure S3 and Table S1.
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Figure 4. smHDP Leads Kill P. falciparum via Parasite DV Lysis and Decrease Parasitemia in a Murine Malaria Model
(A) Parasite plasma membrane and mitochondrial potential was examined during treatment with PMX207 or PMX1207, with no discernible loss of fluorescence,
unlike the positive controls. Compromise of DV integrity wasmonitored with LysoTracker Red, wherein loss of DV fluorescencewas seen within 15min of smHDP
treatment, though no loss of parasite plasma membrane potential occurs.
(B) Loss of DV integrity upon smHDP treatment of PM-II-GFP P. falciparum parasites (green, PM-II-GFP [DV]; blue, parasite nuclei.)
(C) ImageStream flow cytometry shows a dose-dependent increase in PM-II-GFP parasites showing a fluorescence surface area of >2 mm2, an indication of DV
lysis, upon treatment with PMX207 or PMX1207. Intact DVs have fluorescent surface areas <0.2 mm2. Data shown are means ± SEM (*p < 0.05, **p < 0.01).
(D) TEM images reveal complete dissolution of the DV membrane upon PMX207 or PMX1207 treatment, with dispersal of hemozoin crystals (red arrowheads)
throughout the cytoplasm and an accumulation of undigested hemoglobin-containing vesicles (yellow arrowheads). Mock-treated parasites retained a clear
delineating DV membrane (white arrowheads), encapsulating all hemozoin crystals (N, parasite nucleus).
Cell Host & Microbe
PF4 and Drug-like Mimics Kill Malaria Parasites
Cell Host & Microbe 12, 815–823, December 13, 2012 ª2012 Elsevier Inc. 821
Cell Host & Microbe
PF4 and Drug-like Mimics Kill Malaria Parasitesto limit parasite growth in vivo in both a non-ECM and ECM
murine malaria model. PMX207 and PMX1207 antiparasitic
activity was assessed using the 4 day Peters’ suppression test
against P. yoelii 17XNL and P. berghei ANKA (Figures 4E
and 4F). PMX207 completely eliminated parasitemia in both
models on days 4 and 5 while PMX1207 showed a significant
decrease in parasite growth, suppressing parasitemia at least
5-fold over vehicle-treated controls. Both compounds also
increased mouse survival in the ECM model (Figure 4G), with
all PMX207 mice surviving through day 20. These data provide
in vivo validation that smHDP compounds are a promising class
of antimalarials.
DISCUSSION
In this work we show that the human HDP protein, PF4, and its
HDP domain alone (C12) kill Plasmodium parasites by lysing
the parasite DV. Moreover, we screened a library of smHDPs
and found molecules that preserved this mechanism of parasite
killing while increasing potency. Thus, targeting the lysosome-
like vesicles of protozoan parasites may be an evolutionarily
selected mechanism for mammalian hosts to kill Plasmodium
and one that may be exploited for drug discovery. How proteins
such as PF4, just the C12 HDP domain of PF4, or smHDPs enter
host cells is still an open question and beyond the scope of this
work. However, we provide evidence that these molecules enter
only infected erythrocytes and that this entry process can be
blocked by preincubating with protamine sulfate, a cationic
peptide that can also bind to heparin (Figure S1D). This indicates
the importance of initial electrostatic interactions with the
infected host cell membrane or membrane proteins. Since only
infected cells are targeted, and parasite viability is important
for uptake, this suggests that a parasite-derived or activated
endocytosis-like mechanism could allow for large molecules
such as PF4 or C12 to enter, while channels/pores or passive
diffusion could be responsible for smHDP uptake.
In closing, human PF4 has the ability to kill blood-stage
parasites in vitro, and its low hemolytic potential and selective
targeting of the parasite DV endow it with properties that are
well tolerated in the bloodstream. However, it is unlikely that
PF4 would make a useful therapeutic for malaria treatment due
to the cost of goods and potential of increased inflammatory
damage during cerebral malaria. Thus, we believe the develop-
ment of smHDPs may overcome these issues while preserving
this unique mechanism of action; thus, smHDPs represent
a class of small molecules with effective therapeutic potential
for combating this human disease where efforts are currently
challenged with rampant drug resistance.
EXPERIMENTAL PROCEDURES
Parasite Culture and IC50 Determination
P. falciparum parasites were cultured according to standard conditions (Trager
and Jensen, 1976) with minor modifications as outlined in the Supplemental(E) Parasitemias of Swiss Webster mice infected with P. yoelii 17XNL parasitized e
(n = 7), or 20 mg/kg of PMX207 (n = 5). Parasitemia was assessed on days 4 and
(F) Parasitemias of C57BL/6 mice infected with P. berghei ANKA parasitized eryt
(n = 5), or 20 mg/kg of PMX207 (n = 5). Parasitemia was assessed on days 5 and
(G) Survival curves for P. berghei ANKA infected mice. p = 0.0189 in the log rank
822 Cell Host & Microbe 12, 815–823, December 13, 2012 ª2012 ElsInformation. For IC50 determinations, compounds were assayed for 72 hr, after
which the cultures were fixed with a solution of 4% paraformaldehyde and
0.008% glutaraldehyde in PBS prior to permeabilization with 0.25% Triton
X-100 and 5 mM SYTOX Green Nucleic Acid Stain and flow cytometry analysis
(Accuri C6 Flow Cytometer with C-Sampler). IC50 curves were generated using
GraphPad Prism.
Hemolysis
Hemolysis was conducted following removal of culture supernatant before
fixing and transferring to a clear-bottom plate. Absorbance at 541 nm was
measured and compared to a standard curve generated from Triton X-100-
lysed erythrocytes.
Platelet Activation
Platelets were collected from C57BL/6 mice (WT), homozygous PF4 knockout
mice (PF4 KO), and transgenic mice overexpressing human PF4 (hPF4+)
(Eslin et al., 2004) and added to cultures either with or without preactivation
ex vivo with 5 mM AYP. Parasitemia was assessed via flow cytometry after
24 hr treatment.
Parasite Membrane Potential Assays
Parasite-infected erythrocytes were incubated at 37C for 30 min with 1 mM
rhodamine 123 (for parasite plasma membrane potential), 0.2 mM rhodamine
123 (for parasite mitochondrial potential) (del Pilar Crespo et al., 2008), or
10 nM LysoTracker Red (for DV potential). After preincubation, parasites
were treated for 4 hr with the test compound, a 10 mM mixture of the
ionophores monensin (Sigma) and nigericin (Calbiochem) as a positive control
of membrane potential perturbation, or left untreated and then analyzed via
fluorescence microscopy on a Leica DMI6000 B.
Fluorescence Microscopy and Quantification of DV Lysis
Erythrocytes infected with synchronous cultures of PM-II-GFP-expressing
parasites were treated at 30 hr postinvasion (hpi), fixed at the indicated time
points, stained with Hoechst, and imaged by fluorescence microscopy. Cells
were also analyzed on anAmnis ImageStreamXhigh-resolution flowcytometer
withgating forHoechst-positive cells to isolate infectedcells (Ortynet al., 2007).
Peptide Synthesis
Peptides were synthesized via standard solid-phase peptide synthesis
methods as outlined in detail in the Supplemental Information.
smHDP Screen
Synchronized parasites were treated with 500 nM of each smHDP for 72 hr.
Cells were then fixed and assayed for parasitemia via flow cytometry. Com-
pounds were deemed hits if they causedR80% parasite death, as compared
to a 500 nM chloroquine-treated positive control. The Z factor was calculated
using the equation where m represents the means and s represents the stan-
dard deviations of the positive (p) or negative (n) controls (Zhang et al., 1999).
smHDP Testing in Multiple Parasite, Bacterial, and Mammalian Cell
Lines
Synchronized parasite cultures (3D7, NF54;E, Dd2, 7G8, K1, HB3, T2/C6,
INDO, V1/S, MT/s1 [MR4, ATCC]) were treated with top smHDP hits for IC50
comparison. Titrations for the assay were performed as described previously.
Cytotoxicity (EC50) was determined against mouse 3T3 fibroblasts and human
transformed liver HepG2 cells using an MTS viability assay. Bacterial MIC
determination is outlined in the Supplemental Information.
Transmission Electron Microscopy
Synchronous cultures ofP. falciparum parasites were treatedwith either 10 mM
PF4, 500 nM PMX207, or PMX1207. DMSO was used as a negative control.
A detailed description is provided in the Supplemental Information.rythrocytes via i.v. injection and treated with vehicle (n = 5), 5 mg/kg PMX1207
6. Shown are the means ± SEM (*p < 0.05; ***p < 0.001).
hrocytes via i.v. injection and treated with vehicle (n = 10), 5 mg/kg PMX1207
7. Shown are the means ± SEM (*p < 0.05; ***p < 0.001).
Mantel-Cox test. See also Figure S4 and Movie S2.
evier Inc.
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C57BL/6 mice were infected with 2.5 3 104 P. berghei ANKA parasitized
erythrocytes via intravenous injection. Mice were dosed once per day intrave-
nously on days 1–4 with either 5mg/kg PMX1207 (in 20%DMA in saline [n = 5])
or 20 mg/kg PMX207 (in 20% Kleptose HPB [n = 5]) or left untreated (Control,
n = 5). Parasitemias were determined on days 5 and 7 via Giemsa-stained
blood smears. Mice experiments were performed at Johns Hopkins University
(JHU) Bloomberg School of Public Health in accordance with the guidelines of
the JHU Institutional Animal Care and Use Committees.
Statistical Analyses
We analyzed the statistical significance of DV lysis with one-tailed paired
Student’s t tests. Mouse parasitemias were analyzed with a one-way
ANOVA with Dunnett’s post hoc test. A Mantel-Cox log rank test was
performed on the survival data, with a Bonferroni correction for multiple anal-
yses. Significance was assigned to an alpha of 0.01 for DV lysis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, Supplemental
Experimental Procedures, and two movies and can be found with this article
online at http://dx.doi.org/10.1016/j.chom.2012.10.017.
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